Retatrutide vs Semaglutide

The declared receptor profiles differ: retatrutide is described as an agonist at GIP, GLP-1 and glucagon receptors, whereas semaglutide is described as a GLP-1 receptor agonist. Retatrutide is not GLP-3, and the number of named pathways is not a performance ranking.

Both descriptions include lipid-associated changes to exposure, but their structures and receptor profiles differ. Findings from one experimental preparation, species or study design cannot establish the response of the other material.

Retatrutide literature includes a phase 2 clinical trial versus placebo. This identifies evidence in people and its scope; it does not turn that study into a direct comparison with semaglutide or into evidence about a commercial vial.

Retatrutide: Retatrutide is a synthetic acylated peptide derived from the structure of glucose-dependent insulinotropic polypeptide. In research models, it binds to GIP, GLP-1 and glucagon receptors and acts as an agonist of these three signaling pathways. It has been studied in models of metabolic regulation and body composition in preclinical research.

Semaglutide: Semaglutide is a glucagon-like peptide-1 analog with substitutions at positions 8 and 34 and a fatty acid chain attached through a spacer. In preclinical models, it binds to the GLP-1 receptor and acts as an agonist of that pathway. It has been investigated in models of glucose homeostasis and metabolic regulation in animal studies.

Retatrutide: In research models, the molecule acts on three G protein-coupled receptors in the secretin family. Its lipid chain prolongs association with albumin, modifying the exposure profile described in preclinical literature.

Semaglutide: Replacing alanine with Aib at position 8 reduces degradation by dipeptidyl peptidase 4 in in vitro studies. Acylation promotes albumin binding and modifies the kinetics of receptor exposure in experimental models.

A dash means that the catalog does not declare that field for the compound. If neither entry declares a field, the row is omitted. A label purity specification of ≥ 99 % is not an analytical result; results must come from the certificate for the relevant batch.

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Consult each product page for its current presentations, availability, batch documentation and price. This comparison does not freeze commercial information in the research text.

The compendium entries contain the extended definitions, research context and indexed bibliography for each compound. The comparison organizes declared information; it does not replace study-specific interpretation or batch identity evidence.